High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer

Acta Oncologica

Volumn 49, Issue 6, 2010, Pages 861-864

  Choi, In Keun ^a   Kim, Yeul Hong ^a   Kim, Jun Suk ^a   Seo, Jae Hong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 39;

ADULT; AGED; BLOOD ANALYSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GLYCOPROTEINS; GROWTH SUBSTANCES; HUMANS; KAPLAN-MEIERS ESTIMATE; LECTINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954484253     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841861003631503     Document Type: Letter

References (14)

1. Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002;69:25-29
2. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA.Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202.
3. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on cancer stage I and II melanoma. J Clin Oncol 2006;24: 798-803.
4. Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA. Serum YKL-40: A new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 1995;31A:1437-1442
5. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999;79:1494-1499
6. Dehn H, Hogdall EV, Johansen JS, Jorgensen M, Price PA, Engelholm SA, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand 2003;82:287-293
7. Hogdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 2003;10:1535-1538
8. Jensen BV, Johansen JS, Price PA. High levels of serum her-2/neu and YKL-40 independently refl ect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003;9: 4423-34.
9. Junker N, Johansen JS, Andersen CB, Kristjansen PE. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005;48:223-231
10. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004;46:333-340
11. Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J, et al. Chondrex: New marker of joint disease. Clin Chem 1998;44:509-516
12. Saidi A, Javerzat S, Bellahcene A, De Vos J, Bello L, Castronovo V, et al. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 2008;122:2187-2198
13. Mylin AK, Andersen NF, Johansen JS, Abildgaard N, Heickendorff L, Standal T, et al. Serum YKL-40 and bone marrow angiogenesis in multiple myeloma. Int J Cancer 2009; 124:1492-1494
14. Johansen JS, Lottenburger T, Nielsen HJ, Jensen JE, Svendsen MN, Kollerup G, et al. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008;17:2603-2608